Gamete cryopreservation has profoundly transformed assisted reproductive treatments, enabling eggs, sperm, and embryos to be stored for many years while maintaining their viability for future use.
This technique—now one of the most widely implemented in reproductive medicine—has become an invaluable tool for couples wishing to delay parenthood, as well as for individuals facing medical conditions that may compromise fertility (such as cancer or the need for surgical intervention), allowing them to preserve gametes for later use. Furthermore, advances such as vitrification have achieved success rates with frozen oocytes and embryos comparable to those obtained with fresh specimens. These facts raise important questions:

Unlike the older, slow-freezing methods, vitrification is an ultra-rapid cryopreservation technique that prevents the formation of intracellular ice crystals, thereby protecting cellular integrity. It is widely applied for both oocytes and embryos and has demonstrated safety and efficacy.
In the case of oocytes, vitrification permits their preservation for extended periods without deterioration in their initial quality, provided storage is maintained under optimal laboratory conditions.
Vitrified oocytes can be maintained indefinitely without storage time affecting their ability to be fertilized or to result in a viable pregnancy. They remain suitable for use many years after retrieval, as long as thawing and handling are performed in a specialized, qualified laboratory.
If the oocytes are not to be used, they may be donated to other patients or allocated for scientific research, always subject to the donor’s informed consent.
A common concern among women who vitrify their oocytes is whether the procedure affects future fertility. The answer is unequivocal: it does not diminish future fertility potential. Ovarian stimulation protocols are designed to retrieve multiple oocytes in a single cycle without exhausting the ovarian reserve.
It is important to note, however, that oocyte quality is directly dependent on the woman’s age at the time of cryopreservation. Therefore, performing the procedure before the age of 35 is generally recommended, as younger oocytes have a higher probability of leading to a successful pregnancy.
Sperm cryopreservation also permits long-term storage. As with oocytes, the quality of the spermatozoa at the time of freezing is critical to future outcomes.
Sperm banks maintain strict quality-control protocols to ensure sample viability. This option is frequently chosen by oncology patients prior to undergoing fertility-compromising treatments, by men who cannot be present on the day of fertilization, and in donation scenarios.
Blastocyst stage embryo
Embryo vitrification allows for decades-long storage without detrimental effects. There are documented cases of healthy births from embryos frozen many years earlier, with no associated adverse health outcomes in the newborn.
Once thawed at the blastocyst stage, embryos are cultured for 2 to 4 hours to assess blastocyst expansion and survival (days 5–6), before being transferred into the uterine cavity. Clinical success rates depend mainly on embryo quality, the patient’s age, and the condition of the endometrial lining. At IVF-Life, our success rates are above the European average.
It is essential to emphasise that vitrification is now a routine, highly safe procedure. There are no observable differences in perinatal outcomes between babies conceived from frozen gametes or embryos and those conceived from fresh materials.
However, maternal age at the time of gestation remains a significant factor. The older the patient at the time of pregnancy, the greater the obstetric risks—such as spontaneous miscarriage or pregnancy complications—regardless of the age of the gametes or embryos at retrieval.